Betrixaban Drug Asset Due Diligence Report 2026

This Betrixaban Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Withdrawn

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: HOLD / OPTION

Decision memo

Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.

The central underwriting question is whether Betrixaban can convert its Small molecule drug profile and factor Xa biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Betrixaban (query alias: betrixaban)
Modality / target	Small molecule drug; factor Xa; factor Xa inhibitors
Highest global status	Withdrawn
Originator	Millennium Pharmaceuticals, Inc.
Active developers	Not disclosed

The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT03330457	Phase 2	Terminated	18	Change in Anti-Fxa Activity From Baseline to End of Bolus
NCT02596100	Phase 1	Completed	52	Bioequivalence analysis using total area under the curve (Total AUC) after a single dose of Betrixaban in healthy subjects
NCT03397888	Phase 1	Completed	32	PK - Plasma half-life (t1/2)

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Betrixaban in Pediatric Patients

Phase 1; n=21; evaluation: not stated. Reported fields: Maximum Observed Plasma Concentration (Cmax) Of Betrixaban(Geometric Mean) = NA nanograms (ng)/milliliters (mL) (Full Range, 0.200 - 48.5); -; Maximum Observed Plasma Concentration (Cmax) Of Betrixaban(Geometric Mean) = NA nanograms (ng)/milliliters (mL) (Full Range, 0.200 - 2.57)

External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial

Phase 3; n=not disclosed; evaluation: not stated. Reported fields: VTE: c statistic = 0.091(95% CI, 0.011 - 0.172), P-Value = 0.026; VTE: c statistic = 0.091(95% CI, 0.011 - 0.172), P-Value = 0.026

A Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered Andexanet After Dosing to Steady-State With Oral Betrixaban in Healthy Subjects

Phase 2; n=18; evaluation: not stated. Reported fields: Change in Anti-Fxa Activity From Baseline to End of Bolus(Mean) = -23.45 ug/L (Standard Deviation, 7.453); -; Change in Anti-Fxa Activity From Baseline to End of Bolus(Mean) = -26.17 ug/L (Standard Deviation, 16.661)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Betrixaban addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-05-05	Alexion Completes Acquisition of Portola	Approved	US$1,410.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Novel non-oral formulations of factor xa inhibitors and process for preparation thereof”. The milestone feed surfaced a patent-application signal described as “Method for simultaneously and quantitatively analyzing rivaroxaban, apixaban, eldoxaban and betrixaban by using liquid chromatography-tandem mass spectrometry”. The milestone feed surfaced a patent-application signal described as “Betrixaban capsule and preparation method thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

HOLD / OPTION